NeurAxis, Inc.
NRXS
AMEX·Healthcare·Biotechnology·Mkt cap $74.4M
$5.96
▼ -1.81%
P/E
-16.11
Mkt Cap
$74.4M
52-Wk Range
$2.21–$9.33
52-Week Range
$2.21 - $9.33
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 146.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Average volatility.
Growth
Strong growth ahead
Value
Deep value opportunity - significant discount to sector peers
Momentum
Weak
-10.6% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying NRXS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Sep 17, 2026
AUG 11, 2026
Reported EPS of -$0.19 vs -$0.32 consensus (+40.6% surprise). Revenue of $1.9M vs $2.0M expected (-3.6%).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+40.6%
Revenue trend · last 2Q
—
+116%
Q1 26
Q2 26
$1.6M
$1.9M
Margins · last 2Q
Gross
85.9%
Operating
-110.2%
Profit
-118.1%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Craig-Hallum · Mar 20, 2026
vs Industry
How NRXS stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.